Efficacy of Tripterygium glycosides in immune-mediated kidney diseases as a immunomodulation drug in combination with conventional immunosuppressive agents: a systematic review and meta-analysis of randomized controlled trials
BackgroundImmune-mediated kidney diseases involve the immune system attacking the kidneys, resulting in damage and dysfunction. Tripterygium glycosides (TG) are known for their strong immunosuppressive and anti-inflammatory effects and are commonly used alongside traditional immunosuppressive agents...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1525482/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849321273834864640 |
|---|---|
| author | Yaotan Li Yaotan Li Jinyi Hou Jinyi Hou Xiaochang Wu Xiaochang Wu Chang Liu Mengqi Zhou Shijia Lin Weijing Liu Weijing Liu Yaoxian Wang Yaoxian Wang Huijuan Zheng Huijuan Zheng |
| author_facet | Yaotan Li Yaotan Li Jinyi Hou Jinyi Hou Xiaochang Wu Xiaochang Wu Chang Liu Mengqi Zhou Shijia Lin Weijing Liu Weijing Liu Yaoxian Wang Yaoxian Wang Huijuan Zheng Huijuan Zheng |
| author_sort | Yaotan Li |
| collection | DOAJ |
| description | BackgroundImmune-mediated kidney diseases involve the immune system attacking the kidneys, resulting in damage and dysfunction. Tripterygium glycosides (TG) are known for their strong immunosuppressive and anti-inflammatory effects and are commonly used alongside traditional immunosuppressive agents. However, evidence-based support for the combined use of these treatments in immune-mediated kidney diseases remains insufficient and requires further validation.PurposeThe aim of this study is to evaluate the efficacy and safety of TG combined with immunosuppressive agents in the treatment of immune-mediated kidney diseases.Study designSystematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs).MethodsWe searched nine electronic databases for articles from 1 January 2014 to 1 June 2025. We included the RCTs comparing TG combined with immunosuppressive agents versus immunosuppressive agents alone. Meta-analysis was performed according to the Cochrane Handbook.ResultsThirty-six RCTs were included, involving 3,455 patients with various conditions such as membranous nephropathy (MN), IgA nephropathy (IgAN), primary nephrotic syndrome (PNS) and others. The combined use of TG and immunosuppressive agents differs from the use of immunosuppressive agents alone in terms of clinical efficacy (RR = 1.26; 95%CI: 1.22–1.30), improvement in serum creatinine (Cr) (SMD = −0.86; 95%CI: −1.11 to −0.61), blood urea nitrogen (BUN) (SMD = −0.68; 95%CI: −1.05 to −0.31), 24-h urinary total protein (24h-UTP) (SMD = −0.93; 95%CI: −1.13 to −0.74), and serum albumin (ALB) (SMD = 1.30; 95%CI: 1.08–1.52). However, there is no statistically significant difference in the improvement of total cholesterol (TC) (SMD = −0.62; 95%CI: −1.39 to 0.16). In terms of overall safety, the combination therapy shows a statistically significant difference compared to the use of immunosuppressive agents alone (RR = 0.72; 95%CI: 0.58–0.90), but no differences were observed in gastrointestinal issues, liver damage, leukopenia, and infections. Additionally, our analysis found that the combination therapy has a significant advantage over the use of immunosuppressive agents alone in reducing the recurrence rate (RR = 0.21; 95%CI: 0.10–0.44). In terms of mechanisms, the final results indicate that there are differences in interleukin-6 (IL-6) and C-reactive protein (CRP) levels between the two groups, while no differences were observed in interleukin-1 (IL-1) and tumor necrosis factor (TNF-α). However, treatment course, TG dosage, and sample size are important factors influencing the results.ConclusionOur study suggests that the combination of TG with immunosuppressive agents offers more pronounced efficacy in treating immune mediated kidney diseases, without increasing the incidence of adverse reactions. However, our findings may be limited by the quality of the existing studies. High-quality RCTs are needed to provide more accurate evidence.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD42023473530. |
| format | Article |
| id | doaj-art-a97e4b45258d4e338ade119b83cf8a3d |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-a97e4b45258d4e338ade119b83cf8a3d2025-08-20T03:49:49ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-07-011610.3389/fphar.2025.15254821525482Efficacy of Tripterygium glycosides in immune-mediated kidney diseases as a immunomodulation drug in combination with conventional immunosuppressive agents: a systematic review and meta-analysis of randomized controlled trialsYaotan Li0Yaotan Li1Jinyi Hou2Jinyi Hou3Xiaochang Wu4Xiaochang Wu5Chang Liu6Mengqi Zhou7Shijia Lin8Weijing Liu9Weijing Liu10Yaoxian Wang11Yaoxian Wang12Huijuan Zheng13Huijuan Zheng14Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, ChinaBeijing University of Chinese Medicine, Beijing, ChinaDongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, ChinaBeijing University of Chinese Medicine, Beijing, ChinaDongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, ChinaBeijing University of Chinese Medicine, Beijing, ChinaBeijing University of Chinese Medicine, Beijing, ChinaBeijing Puren Hospital, Beijing, ChinaDongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, ChinaDongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, ChinaRenal Research Institution of Beijing University of Chinese Medicine, Beijing, ChinaRenal Research Institution of Beijing University of Chinese Medicine, Beijing, ChinaHenan University of Chinese Medicine, Zhengzhou, ChinaDongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, ChinaRenal Research Institution of Beijing University of Chinese Medicine, Beijing, ChinaBackgroundImmune-mediated kidney diseases involve the immune system attacking the kidneys, resulting in damage and dysfunction. Tripterygium glycosides (TG) are known for their strong immunosuppressive and anti-inflammatory effects and are commonly used alongside traditional immunosuppressive agents. However, evidence-based support for the combined use of these treatments in immune-mediated kidney diseases remains insufficient and requires further validation.PurposeThe aim of this study is to evaluate the efficacy and safety of TG combined with immunosuppressive agents in the treatment of immune-mediated kidney diseases.Study designSystematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs).MethodsWe searched nine electronic databases for articles from 1 January 2014 to 1 June 2025. We included the RCTs comparing TG combined with immunosuppressive agents versus immunosuppressive agents alone. Meta-analysis was performed according to the Cochrane Handbook.ResultsThirty-six RCTs were included, involving 3,455 patients with various conditions such as membranous nephropathy (MN), IgA nephropathy (IgAN), primary nephrotic syndrome (PNS) and others. The combined use of TG and immunosuppressive agents differs from the use of immunosuppressive agents alone in terms of clinical efficacy (RR = 1.26; 95%CI: 1.22–1.30), improvement in serum creatinine (Cr) (SMD = −0.86; 95%CI: −1.11 to −0.61), blood urea nitrogen (BUN) (SMD = −0.68; 95%CI: −1.05 to −0.31), 24-h urinary total protein (24h-UTP) (SMD = −0.93; 95%CI: −1.13 to −0.74), and serum albumin (ALB) (SMD = 1.30; 95%CI: 1.08–1.52). However, there is no statistically significant difference in the improvement of total cholesterol (TC) (SMD = −0.62; 95%CI: −1.39 to 0.16). In terms of overall safety, the combination therapy shows a statistically significant difference compared to the use of immunosuppressive agents alone (RR = 0.72; 95%CI: 0.58–0.90), but no differences were observed in gastrointestinal issues, liver damage, leukopenia, and infections. Additionally, our analysis found that the combination therapy has a significant advantage over the use of immunosuppressive agents alone in reducing the recurrence rate (RR = 0.21; 95%CI: 0.10–0.44). In terms of mechanisms, the final results indicate that there are differences in interleukin-6 (IL-6) and C-reactive protein (CRP) levels between the two groups, while no differences were observed in interleukin-1 (IL-1) and tumor necrosis factor (TNF-α). However, treatment course, TG dosage, and sample size are important factors influencing the results.ConclusionOur study suggests that the combination of TG with immunosuppressive agents offers more pronounced efficacy in treating immune mediated kidney diseases, without increasing the incidence of adverse reactions. However, our findings may be limited by the quality of the existing studies. High-quality RCTs are needed to provide more accurate evidence.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD42023473530.https://www.frontiersin.org/articles/10.3389/fphar.2025.1525482/fullTripterygium glycosidesimmune-mediated kidney diseasesrandomized controlled trialsimmunosuppressive agentsmeta-analysis |
| spellingShingle | Yaotan Li Yaotan Li Jinyi Hou Jinyi Hou Xiaochang Wu Xiaochang Wu Chang Liu Mengqi Zhou Shijia Lin Weijing Liu Weijing Liu Yaoxian Wang Yaoxian Wang Huijuan Zheng Huijuan Zheng Efficacy of Tripterygium glycosides in immune-mediated kidney diseases as a immunomodulation drug in combination with conventional immunosuppressive agents: a systematic review and meta-analysis of randomized controlled trials Frontiers in Pharmacology Tripterygium glycosides immune-mediated kidney diseases randomized controlled trials immunosuppressive agents meta-analysis |
| title | Efficacy of Tripterygium glycosides in immune-mediated kidney diseases as a immunomodulation drug in combination with conventional immunosuppressive agents: a systematic review and meta-analysis of randomized controlled trials |
| title_full | Efficacy of Tripterygium glycosides in immune-mediated kidney diseases as a immunomodulation drug in combination with conventional immunosuppressive agents: a systematic review and meta-analysis of randomized controlled trials |
| title_fullStr | Efficacy of Tripterygium glycosides in immune-mediated kidney diseases as a immunomodulation drug in combination with conventional immunosuppressive agents: a systematic review and meta-analysis of randomized controlled trials |
| title_full_unstemmed | Efficacy of Tripterygium glycosides in immune-mediated kidney diseases as a immunomodulation drug in combination with conventional immunosuppressive agents: a systematic review and meta-analysis of randomized controlled trials |
| title_short | Efficacy of Tripterygium glycosides in immune-mediated kidney diseases as a immunomodulation drug in combination with conventional immunosuppressive agents: a systematic review and meta-analysis of randomized controlled trials |
| title_sort | efficacy of tripterygium glycosides in immune mediated kidney diseases as a immunomodulation drug in combination with conventional immunosuppressive agents a systematic review and meta analysis of randomized controlled trials |
| topic | Tripterygium glycosides immune-mediated kidney diseases randomized controlled trials immunosuppressive agents meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1525482/full |
| work_keys_str_mv | AT yaotanli efficacyoftripterygiumglycosidesinimmunemediatedkidneydiseasesasaimmunomodulationdrugincombinationwithconventionalimmunosuppressiveagentsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT yaotanli efficacyoftripterygiumglycosidesinimmunemediatedkidneydiseasesasaimmunomodulationdrugincombinationwithconventionalimmunosuppressiveagentsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT jinyihou efficacyoftripterygiumglycosidesinimmunemediatedkidneydiseasesasaimmunomodulationdrugincombinationwithconventionalimmunosuppressiveagentsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT jinyihou efficacyoftripterygiumglycosidesinimmunemediatedkidneydiseasesasaimmunomodulationdrugincombinationwithconventionalimmunosuppressiveagentsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT xiaochangwu efficacyoftripterygiumglycosidesinimmunemediatedkidneydiseasesasaimmunomodulationdrugincombinationwithconventionalimmunosuppressiveagentsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT xiaochangwu efficacyoftripterygiumglycosidesinimmunemediatedkidneydiseasesasaimmunomodulationdrugincombinationwithconventionalimmunosuppressiveagentsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT changliu efficacyoftripterygiumglycosidesinimmunemediatedkidneydiseasesasaimmunomodulationdrugincombinationwithconventionalimmunosuppressiveagentsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT mengqizhou efficacyoftripterygiumglycosidesinimmunemediatedkidneydiseasesasaimmunomodulationdrugincombinationwithconventionalimmunosuppressiveagentsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT shijialin efficacyoftripterygiumglycosidesinimmunemediatedkidneydiseasesasaimmunomodulationdrugincombinationwithconventionalimmunosuppressiveagentsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT weijingliu efficacyoftripterygiumglycosidesinimmunemediatedkidneydiseasesasaimmunomodulationdrugincombinationwithconventionalimmunosuppressiveagentsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT weijingliu efficacyoftripterygiumglycosidesinimmunemediatedkidneydiseasesasaimmunomodulationdrugincombinationwithconventionalimmunosuppressiveagentsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT yaoxianwang efficacyoftripterygiumglycosidesinimmunemediatedkidneydiseasesasaimmunomodulationdrugincombinationwithconventionalimmunosuppressiveagentsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT yaoxianwang efficacyoftripterygiumglycosidesinimmunemediatedkidneydiseasesasaimmunomodulationdrugincombinationwithconventionalimmunosuppressiveagentsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT huijuanzheng efficacyoftripterygiumglycosidesinimmunemediatedkidneydiseasesasaimmunomodulationdrugincombinationwithconventionalimmunosuppressiveagentsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT huijuanzheng efficacyoftripterygiumglycosidesinimmunemediatedkidneydiseasesasaimmunomodulationdrugincombinationwithconventionalimmunosuppressiveagentsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials |